NTRA News and Press, Natera Inc. From 01/30/23

Summary BNGO reported preliminary Q4 results, showing acceptable core business performance. Aggressive expansion into capital-intensive markets could put significant pressure on BNGO's balance sheet. Recently-introduced LDTs will likely have a limited impact on revenue growth. ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers Sy...

The shares of Natera ( NASDAQ: NTRA ) and Myriad Genetics ( NASDAQ: MYGN ) climbed, and those of Exact Sciences ( NASDAQ: EXAS ) and Veracyte ( NASDAQ: VCYT ) fell in pre-market Wednesday after Raymond James changed its ratings in the gene-based diagnostic space. ...

New predictive data evaluates patient outcomes up to 24.8 months post-surgery, confirms findings presented at ASCO GI 2022 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine , which demonst...

Summary Despite its price surge, EXAS's valuation remains aligned with industry averages. EXAS has one of the clearest profitability paths in a market characterized by heavy losses stemming from aggressive growth initiatives. We might see some profit-taking in the coming weeks, but ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023 at 9:45 a.m. PT (12:45 p.m. ET). Members of Natera management will deliver a present...

Summary Sema4's restructuring plan has a number of potential downsides that could affect the company's cash position in the coming few quarters. The booting of the CEO signals the start of a strategic focus on short-term survival away from long-term growth. Even if management succee...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced its support for a recent guideline update by the International Society for Heart and Lung Transplantation (ISHLT), which includes the use of donor-derived cfDNA (dd-cfDNA) testing for surveillance of heart ...

Summary CDNA's share repurchase program will reduce outstanding shares by 8% based on current prices. This and management's short-term profitability ambitions warrant a rating upgrade. The company has a strong balance sheet, with enough dry powder to leverage itself into profitability a...

Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers PR Newswire Across all subtypes, in a real-world cohort of >200 patients and >900 plasma samples, the presence of ctDNA at any time w...